News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,481 Results
Type
Article (41506)
Company Profile (460)
Press Release (656515)
Section
Business (208347)
Career Advice (1999)
Deals (35935)
Drug Delivery (91)
Drug Development (83263)
Employer Resources (169)
FDA (16323)
Job Trends (15037)
News (351995)
Policy (32972)
Tag
Academia (2619)
Alliances (50557)
Alzheimer's disease (1257)
Approvals (16234)
Artificial intelligence (123)
Bankruptcy (361)
Best Places to Work (11656)
Biotechnology (345)
Breast cancer (105)
Cancer (917)
Career advice (1669)
Cell therapy (207)
Clinical research (65641)
Collaboration (336)
Compensation (159)
COVID-19 (2580)
Cystic fibrosis (82)
Data (848)
Diabetes (132)
Diagnostics (6149)
Drug pricing (83)
Earnings (85317)
Employer resources (147)
Events (112189)
Executive appointments (244)
FDA (16759)
Funding (300)
Gene therapy (161)
GLP-1 (589)
Government (4401)
Healthcare (18974)
Infectious disease (2653)
Inflammatory bowel disease (107)
Interviews (308)
IPO (16539)
Job creations (3693)
Job search strategy (1427)
Layoffs (434)
Legal (7922)
Lung cancer (158)
Manufacturing (152)
Medical device (13288)
Medtech (13293)
Mergers & acquisitions (19392)
Metabolic disorders (371)
Neuroscience (1508)
NextGen Class of 2024 (6727)
Non-profit (4530)
Northern California (1194)
Obesity (222)
Opinion (194)
Patents (95)
People (57459)
Pharmaceutical (86)
Phase I (20544)
Phase II (28964)
Phase III (21455)
Pipeline (205)
Postmarket research (2590)
Preclinical (8811)
Radiopharmaceuticals (250)
Rare diseases (192)
Real estate (5996)
Regulatory (21863)
Research institute (2402)
Resumes & cover letters (351)
Southern California (1083)
Startups (3745)
United States (11821)
Vaccines (550)
Weight loss (171)
Date
Last 7 days (795)
Last 30 days (2762)
Last 365 days (36629)
2024 (31054)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33025)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27993)
Location
Africa (731)
Arizona (194)
Asia (38390)
Australia (6379)
California (2756)
Canada (1170)
China (210)
Colorado (118)
Connecticut (126)
Europe (83666)
Florida (388)
Georgia (98)
Illinois (318)
Indiana (178)
Kansas (98)
Maryland (520)
Massachusetts (2279)
Michigan (144)
Minnesota (252)
New Jersey (821)
New York (840)
North Carolina (714)
Northern California (1194)
Ohio (124)
Pennsylvania (744)
South America (1105)
Southern California (1083)
Texas (386)
Washington State (329)
698,481 Results for "vtv therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the first patient has been screened in the Company’s CATT1 pivotal trial evaluating cadisegliatin as an adjunct treatment of type 1 diabetes (T1D).
June 24, 2024
·
5 min read
Business
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments.
May 9, 2024
·
8 min read
Drug Development
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. today announced the submission of the study protocol to the FDA for the Company’s first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin , in adults diagnosed with T1D.
March 4, 2024
·
4 min read
Bio NC
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA.
March 1, 2024
·
3 min read
Business
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
March 13, 2024
·
10 min read
Press Releases
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
August 9, 2024
·
9 min read
Drug Development
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
vTv Therapeutics Inc. announced that it has closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, LLC and the JDRF T1D Fund, of 464,377 shares of common stock at a price of $11.81 per share, which is the 45 day VWAP ended on January 29, 2024, and pre-funded warrants for 3,853,997 shares of common stock in lieu of vTv common stock in a private placement financing.
February 28, 2024
·
5 min read
Bio NC
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
vTv Therapeutics Inc. announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for total proceeds to vTv of approximately $4.4 million.
November 1, 2023
·
4 min read
Press Releases
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
July 29, 2024
·
3 min read
Business
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
vTv Therapeutics Inc. announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately.
November 2, 2023
·
4 min read
1 of 69,849
Next